<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689129</url>
  </required_header>
  <id_info>
    <org_study_id>EFC12449</org_study_id>
    <secondary_id>U1111-1130-3513</secondary_id>
    <nct_id>NCT01689129</nct_id>
  </id_info>
  <brief_title>Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus</brief_title>
  <acronym>EDITION JP I</acronym>
  <official_title>A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of
      change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese
      patients with type 1 diabetes mellitus

      Secondary Objectives:

      To compare a new formulation of insulin glargine and Lantus in terms of change in fasting
      plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose
      (SMPG) profile.

      To compare a new formulation of insulin glargine and Lantus in terms of occurrence of
      hypoglycemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study will consist of:

        -  Up to 2-week screening period;

        -  6-month open-label comparative efficacy and safety treatment period;

        -  6-month open-label comparative safety extension period;

        -  4-week post-treatment safety follow-up period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>baseline, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HbA1c responders (HbA1c &lt; 7%; &lt; 6.5%)</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-basal insulin injection SMPG</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 8-point SMPG profiles</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in variability of plasma glucose profile</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily basal insulin dose</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with various types of Hypoglycemia Events</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>New formulation of insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily in the evening on-top of mealtime insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus (insulin glargine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily in the evening on-top of mealtime insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine new formulation (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>New formulation of insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine (HOE901) (Lantus)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>Lantus (insulin glargine)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with type 1 diabetes mellitus

        Exclusion criteria:

          -  Age &lt; 18 years at screening visit;

          -  HbA1c &lt; 7.0 % or &gt; 10.0 % (national glycohemoglobin standardization program [NGSP]
             value) at screening visit;

          -  Patients less than 1 year before screening visit on any basal plus mealtime insulin;

          -  Patients not on stable insulin dose (±20% total basal insulin dose) in the last 30
             days prior to screening visit;

          -  Patients using pre-mix insulins, human regular insulin as mealtime insulin and/or any
             glucose-lowering drugs other than basal insulin and mealtime rapid-insulin analogue in
             the last 3 months before screening visit;

          -  Use of an insulin pump in the last 6 months before screening visit and/or plan to
             switch to insulin pump in next 12 months;

          -  Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic
             ketoacidosis in the last 6 months before screening visit;

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eq, laser, surgical
             treatment or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392119</name>
      <address>
        <city>Amagasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392106</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392107</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392110</name>
      <address>
        <city>Ebina-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392115</name>
      <address>
        <city>Higashiosaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392117</name>
      <address>
        <city>Izumisano-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392109</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392101</name>
      <address>
        <city>Koriyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392121</name>
      <address>
        <city>Kurashiki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392112</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392120</name>
      <address>
        <city>Nishinomiya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392113</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392116</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392118</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392104</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392105</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392111</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392114</name>
      <address>
        <city>Takatsuki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392122</name>
      <address>
        <city>Tokushima-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392103</name>
      <address>
        <city>Tomioka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392102</name>
      <address>
        <city>Ushiku-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392108</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

